321 related articles for article (PubMed ID: 27654837)
1. Short-term efficacy and safety of ranibizumab for macular oedema secondary to retinal vein occlusion in Japanese patients.
Kamei M; Terasaki H; Yoshimura N; Shiraga F; Ogura Y; Grotzfeld AS; Pilz S; Ishibashi T
Acta Ophthalmol; 2017 Feb; 95(1):e29-e35. PubMed ID: 27654837
[TBL] [Abstract][Full Text] [Related]
2. Real-World Outcomes of Ranibizumab Treatment in French Patients with Visual Impairment due to Macular Edema Secondary to Retinal Vein Occlusion: 24-Month Results from the BOREAL-RVO Study.
Glacet-Bernard A; Girmens JF; Kodjikian L; Delcourt C; Fajnkuchen F; Creuzot-Garcher C; San Nicolas N; Massin P
Ophthalmic Res; 2023; 66(1):824-834. PubMed ID: 36972579
[TBL] [Abstract][Full Text] [Related]
3. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
5. Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER.
Tadayoni R; Waldstein SM; Boscia F; Gerding H; Pearce I; Priglinger S; Wenzel A; Barnes E; Gekkieva M; Pilz S; Monés J;
Ophthalmology; 2016 Jun; 123(6):1332-44. PubMed ID: 27039022
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Ranibizumab in Asian Patients with Branch Retinal Vein Occlusion: Results from the Randomized BLOSSOM Study.
Wei W; Weisberger A; Zhu L; Cheng Y; Liu C;
Ophthalmol Retina; 2020 Jan; 4(1):57-66. PubMed ID: 31902472
[TBL] [Abstract][Full Text] [Related]
7. Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study.
Larsen M; Waldstein SM; Boscia F; Gerding H; Monés J; Tadayoni R; Priglinger S; Wenzel A; Barnes E; Pilz S; Stubbings W; Pearce I;
Ophthalmology; 2016 May; 123(5):1101-11. PubMed ID: 26896124
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
9. Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial.
Campochiaro PA; Hafiz G; Mir TA; Scott AW; Solomon S; Zimmer-Galler I; Sodhi A; Duh E; Ying H; Wenick A; Shah SM; Do DV; Nguyen QD; Kherani S; Sophie R
Ophthalmology; 2015 Jul; 122(7):1426-37. PubMed ID: 25972260
[TBL] [Abstract][Full Text] [Related]
10. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months.
Winterhalter S; Eckert A; Vom Brocke GA; Schneider A; Pohlmann D; Pilger D; Joussen AM; Rehak M; Grittner U
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):267-279. PubMed ID: 29185099
[TBL] [Abstract][Full Text] [Related]
11. Sustained Benefits of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-Month Results of the BRIGHTER Study.
Tadayoni R; Waldstein SM; Boscia F; Gerding H; Gekkieva M; Barnes E; Das Gupta A; Wenzel A; Pearce I;
Ophthalmology; 2017 Dec; 124(12):1778-1787. PubMed ID: 28807635
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.
Campochiaro PA; Sophie R; Pearlman J; Brown DM; Boyer DS; Heier JS; Marcus DM; Feiner L; Patel A;
Ophthalmology; 2014 Jan; 121(1):209-219. PubMed ID: 24112944
[TBL] [Abstract][Full Text] [Related]
13. [Two-Year Follow-up Results of Patients with Macular Oedema Due to Retinal Vein Occlusion Treated with Ranibizumab].
Hladíková Z; Klofáčová E; Kalvodová B
Cesk Slov Oftalmol; 2017; 73(2):43-51. PubMed ID: 28931295
[TBL] [Abstract][Full Text] [Related]
14. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
15. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study.
Feltgen N; Hattenbach LO; Bertelmann T; Callizo J; Rehak M; Wolf A; Berk H; Eter N; Lang GE; Pielen A; Schmitz-Valckenberg S; Quiering C; Rose U; Hoerauf H;
Acta Ophthalmol; 2018 Dec; 96(8):e933-e941. PubMed ID: 29855153
[TBL] [Abstract][Full Text] [Related]
17. Different Factors Associated with 2-Year Outcomes in Patients with Branch versus Central Retinal Vein Occlusion Treated with Ranibizumab.
Sophie R; Wang PW; Channa R; Quezada-Ruiz C; Clark A; Campochiaro PA
Ophthalmology; 2019 Dec; 126(12):1695-1702. PubMed ID: 31543350
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome.
Farinha C; Marques JP; Almeida E; Baltar A; Santos AR; Melo P; Costa M; Figueira J; Cachulo ML; Pires I; Silva R
Ophthalmic Res; 2015; 55(1):10-8. PubMed ID: 26540281
[TBL] [Abstract][Full Text] [Related]
19. Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography.
Bhisitkul RB; Campochiaro PA; Shapiro H; Rubio RG
Ophthalmology; 2013 May; 120(5):1057-63. PubMed ID: 23415775
[TBL] [Abstract][Full Text] [Related]
20. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Pichi F; Elbarky AM; Elhamaky TR
Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
